BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
The purpose of this study is to determine

 -  whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe,
 tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms

 -  whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more
 efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg
This study has previously been posted by Berlex, Inc. and Schering AG, Germany. Berlex, Inc.
 has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been
 renamed to Bayer Schering Pharma AG, Germany.

 Bayer HealthCare Pharmaceuticals, Inc.and Bayer Schering Pharma AG, Germany are the sponsors
 of the trial.
Inclusion Criteria:

 -  Female and male patients

 -  Aged 18-55 years

 -  Diagnosis of RRMS (Relapsing-Remitting Multiple Sclerosis), EDSS score of 0 to 5.0

 -  Treatment-naive to IFNB or Copaxone

 Exclusion Criteria:

 -  Neurological progression at disease onset or between relapses

 -  Serious or acute heart diseases

 -  History of severe depression or suicide attempt

 -  Serious or acute liver, renal or bone marrow dysfunction

 -  Monoclonal gammopathy

 -  Known allergy to Gadolinium-DTPA, to IFNs (Interferons), to glatiramer acetate, to
 human albumin or to mannitol

 -  Pregnancy or lactation